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ABSTRACT 
Bone is a dynamic tissue that responds to many stressors including physical stress and certain disease 
states.  Chronic systemic inflammatory conditions, like inflammatory bowel disease (IBD), result in 
increased bone resorption and decreased bone formation leading to low bone mass and high fracture 
incidence. There currently are no effective, safe treatments for IBD. Irisin is a hormone that is released 
during exercise and has previously been shown to increase bone mass. PURPOSE: Determine if exogenous 
treatment with irisin can mitigate the inflammatory insult of chronic IBD on bone. We hypothesized that 
young male rats with induced IBD and treatment with exogenous irisin would have increased bone 
formation rate (BFR) and mitigated loss of bone mineral density compared to rats with only IBD. 
METHOD: Male Sprague Dawley rats (2 months) were divided into four groups: controls (CON), those 
given dextran sodium sulfate in drinking water to induce IBD (DSS), CON rats given exogenous irisin 
(CON+IR), and DSS rats given exogenous irisin (DSS+IR). n per group=8.. Irisin injections began one week 
after initiation of IBD for the remainder of the four week protocol. RESULTS: Peripheral quantitative 
computed tomography (pQCT) of the proximal tibia metaphysis showed a significant decrease in total 
bone mineral content and volumetric bone mineral density (cortical shell+cancellous core) in both DSS 
groups compared to both control groups. Dynamic histomorphomery revealed higher cancellous BFR due 
to irisin treatment in both CON and DSS rats resulting in DSS+IR having higher BFR than DSS. This was 
due largely to increases in mineralized surface indicating increased numbers of osteoblast teams. At the 
midshaft tibia, BFR was higher in DSS+IR, but not significantly different than DSS alone. This change was 
due more to increases in mineral apposition rate indicating higher activity of osteoblast teams. 
CONCLUSION: In this study, we demonstrated that rats with DSS have low bone mass similar to patients 
with IBD. Although irisin did not mitigate this bone loss, our data indicates over time it would likely lead 
to improved bone mass due to increases in bone formation. Additionally, our data indicate greater 
improvements in BFR in the cancellous bone, a more active bone compartment, than the midshaft tibia, but 
slight increases in mineral apposition rate at this site demonstrate improved osteoblast activity due to 
irisin. Since IBD is a chronic, life-long disease, our data highlights the potential benefit of exogenous irisin 
treatment as well as exercise therapy for patients with IBD.  
 
